Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clear Cell Renal Cell Carcinoma (ccRCC): early-phase trial registry
5 of 6 indexed Clear Cell Renal Cell Carcinoma (ccRCC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Clear Cell Renal Cell Carcinoma (ccRCC): 6 US clinical trials tracked, 5 recruiting.
Clear Cell Renal Cell Carcinoma (ccRCC) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition clear-cell-renal-cell-carcinoma-ccrcc
OPEN 5 | RECR 83% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)
Clear Cell Renal Cell Carcinoma (ccRCC) lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clear Cell Renal Cell Carcinoma (ccRCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clear Cell Renal Cell Carcinoma (ccRCC) is recruiting above its size-band peers.
5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clear Cell Renal Cell Carcinoma (ccRCC) research.
Regeneron Pharmaceuticals accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Clear Cell Renal Cell Carcinoma (ccRCC) enrolment sits around 300 participants.
Median target enrolment is 300 among the 6 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Clear Cell Renal Cell Carcinoma (ccRCC) research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
NCT03972657
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
NCT06026410
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT06413680
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Brian Rini
NCT07188896
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03634540
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Clear Cell Renal Cell Carcinoma (ccRCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clear Cell Renal Cell Carcinoma (ccRCC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clear Cell Renal Cell Carcinoma (ccRCC) page
6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Clear Cell Renal Cell Carcinoma (ccRCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Clear Cell Renal Cell Carcinoma (ccRCC) trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clear Cell Renal Cell Carcinoma (ccRCC) condition card totals 6 registered trials; most-linked intervention Cemiplimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.